Aktuellt
SENASTE
BB Biotech’s team of industry experts have managed to outperform the Nasdaq biotech index (NBI) the last three, five and 10 years. The fund’s clearly defined strategy of investing in listed mid and small cap biotech companies has paid off. Investors in the fund have therefore historically had exposure to an industry with great long-term prospects for growth, while steering clear of many of the pitfalls this sector also offers for non-specialist investors.
LÄS MER
